Abstract: The invention relates to a method for controlling scams in which a phone call requests a return call to a target number, comprising the following steps: collecting signalling data of phone calls made via a telephone network (2); detecting suspicious calls from signalling data collected and using a detection algorithm, and for each suspicious call detected, identifying a suspicious number; comparing the suspicious number with a number and/or at least one range of certified target numbers contained in a certification database, and defining a risk profile for the suspicious number accordingly. Methods and systems for controlling phone scams.

Abstract: In an embodiment, an apparatus includes a first baseband section to receive a calibration signal; a first radio frequency (RF) section configured to generate a RF calibration signal based on modulating the calibration signal. The calibration signal comprises an orthogonal code based signal. The apparatus includes a second RF section to receive the RF calibration signal and generate a received calibration signal based on demodulating the RF calibration signal; a calibration section; a first antenna electrically coupled to the first RF section and configured to transmit the RF calibration signal; and a second antenna electrically coupled to the second RF section and configured to receive the RF calibration signal. The calibration section is configured to determine one or more of gain, baseband delay, or RF delay to calibrate the first RF section; and the second antenna is switchable between receiving the RF calibration signal and transmitting an encoded data signal.

Abstract: Compounds of Formula (I): pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates thereof.

Abstract: This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, and processes for making such modulators.

Abstract: In an embodiment, an apparatus includes a transmit section including a first baseband section and a first radio frequency (RF) section, wherein the transmit section is configured to receive a calibration signal, the first RF section is configured to generate a RF calibration signal based on modulating the calibration signal. The calibration signal comprises an orthogonal code based signal; and a receive section configured to receive the RF calibration signal over-the-air, the receive section includes a second RF section and a calibration section, the second RF section is configured to generate a received calibration signal based on the RF calibration signal, the received calibration signal and a reference signal associated with the RF calibration signal comprise inputs to the calibration section and the calibration section is configured to determine one or more of gain, baseband delay, or RF delay compensation values, based on the inputs, to calibrate the transmit section.

Abstract: The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R1, R2, R3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.

Abstract: Compounds of Formula I: pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.

Abstract: Compounds of Formula (I): pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates thereof.

Abstract: In an embodiment, an apparatus includes a transmit section including a first baseband section and a first radio frequency (RF) section, wherein the transmit section is configured to receive a calibration signal, the first RF section is configured to generate a RF calibration signal based on modulating the calibration signal. The calibration signal comprises an orthogonal code based signal; and a receive section configured to receive the RF calibration signal over-the-air, the receive section includes a second RF section and a calibration section, the second RF section is configured to generate a received calibration signal based on the RF calibration signal, the received calibration signal and a reference signal associated with the RF calibration signal comprise inputs to the calibration section and the calibration section is configured to determine one or more of gain, baseband delay, or RF delay compensation values, based on the inputs, to calibrate the transmit section.

Abstract: The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R1, R2, R3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.

Abstract: This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis by administering such modulators and pharmaceutical compositions, and processes for making such modulators.

Abstract: In an embodiment, an apparatus included in a communications system includes a transmit section including a first baseband section and a first radio frequency (RF) section, wherein the transmit section is configured to receive a calibration signal, the first RF section is configured to generate a RF calibration signal based on the calibration signal, and wherein the calibration signal comprises an orthogonal code based signal; and a receive section configured to receive the RF calibration signal over-the-air, wherein the receive section includes a second RF section and a calibration section, wherein the second RF section is configured to generate a received calibration signal based on the RF calibration signal, and wherein the calibration section is configured to determine one or more of gain, baseband delay, or RF delay compensation values, based on the inputs, to calibrate the transmit section.

Abstract: Techniques for receiving data at a physical coding sublayer (PCS) transmit structure from a media access control (MAC) sublayer are provided. A PCS transmit structure is configured to receive data from a MAC sublayer, the PCS transmit structure comprising a first FEC hardware module that performs FEC encoding, in a first clock domain, on the data to generate FEC encoded data. Further, a PCS receive structure configured to receive the FEC encoded data from the PCS transmit structure, the PCS receive structure comprising a second FEC hardware module is configured to perform FEC decoding, in the second clock domain, on the FEC encoded data to generate FEC decoded data.

Abstract: An apparatus and method are described, the apparatus comprising: a cache comprising a plurality of entries, each associated with a partition identifier; storage circuitry to store counters, each indicative of a number of entries in the cache associated with respective partition identifiers; and cache control circuitry responsive to a request identifying a given partition identifier to control allocation of an entry dependent on the counter associated with the given partition identifier. The cache control circuitry increments the counter associated with the given partition identifier in response to an entry associated with the given partition identifier being allocated, and decrements the counter associated with the given partition identifier in response to an entry associated with the given partition identifier being evicted or replaced.

Abstract: Compounds of Formula I: pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.

Abstract: An underdrain assembly for filtering particulates from a fluid having an upper structure connected to a bottom plate. At least one flow control vane is positioned between the upper structure and the bottom plate for directing and managing fluid flow through the assembly. The upper structure can have first and second filtration members, the second filtration member positioned between the first filtration member and the bottom plate. The second filtration member can have a shape that restricts fluid flow within the underdrain. The underdrain can have air and water inlets. The water inlet can have an end with a plate covering an upper portion thereof. The end can also include an opening having an angular cut forming an angle with respect to a longitudinal axis of the water inlet. Thus arranged, air is prevented from migrating out the water line. A resilient mounting arrangement for the underdrain is also disclosed.

Abstract: This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, and processes for making such modulators.

Abstract: An apparatus and method are described, the apparatus comprising: a cache comprising a plurality of entries, each associated with a partition identifier; storage circuitry to store counters, each indicative of a number of entries in the cache associated with respective partition identifiers; and cache control circuitry responsive to a request identifying a given partition identifier to control allocation of an entry dependent on the counter associated with the given partition identifier. The cache control circuitry increments the counter associated with the given partition identifier in response to an entry associated with the given partition identifier being allocated, and decrements the counter associated with the given partition identifier in response to an entry associated with the given partition identifier being evicted or replaced.

Abstract: The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R1, R2, R3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.

Abstract: An underdrain assembly for filtering particulates from a fluid having an upper structure connected to a bottom plate. At least one flow control vane is positioned between the upper structure and the bottom plate for directing and managing fluid flow through the assembly. The upper structure can have first and second filtration members, the second filtration member positioned between the first filtration member and the bottom plate. The second filtration member can have a shape that restricts fluid flow within the underdrain. The underdrain can have air and water inlets. The water inlet can have an end with a plate covering an upper portion thereof. The end can also include an opening having an angular cut forming an angle with respect to a longitudinal axis of the water inlet. Thus arranged, air is prevented from migrating out the water line. A resilient mounting arrangement for the underdrain is also disclosed.